Close this search box.
Close this search box.

The Clinical Impact of the T2Candida Panel in the Management of Candidemia

Dr. George Alangaden, Senior Staff Physician Director, Transplant Infectious Diseases, Medical Director of Infection Prevention, Henry Ford Hospital System (HFHS), focuses on the following areas:

  1. Rationale for the adoption of T2 Magnetic Resonance (T2MR) at HFHS
  2. Implementation process of T2MR at HFHS
  3. Impact of the T2MR technology on the hospital and patients

Dr. Alangaden discussed some key findings on the impact of T2MR, including:

  • 4-day reduction in the length of stay in the hospital per patient;
  • 7-day reduction in the length of stay in the ICU per patient; and
  • 75% of patients with a negative T2MR result had antifungals stopped or de-escalated.

Potential study populations

  • High risk patients or patients selected to use last line antibiotics

  • Patients who are part of a stewardship program

  • Patients with history of antibiotic use

  • Patients not responsive to current therapy

  • Patients who are immunocompromised

In addition to the presentation, the May 2017 webinar also included a Q&A section with Dr. Alangaden, as well as Dr. Linoj Samuel, Division Head, Clinical Microbiology, and Rachel Kenney, PharmD, Pharmacy Specialist of Antimicrobial Stewardship, both from HFHS as well. During the Q&A, they discussed the potential cost savings from the discontinued or reduced use of antifungal therapy alone, educational efforts to create understanding and proper use, initial challenges of implementation in the laboratory, and steps taken to address those challenges.

According to the CDC, of the 154 million prescriptions for antibiotics written in doctors’ offices and emergency departments each year, 30% are unnecessary.12


Over 200 studies published in peer-reviewed journals have featured T2MR in a breadth of applications.